[期刊]
  • 《Hematological oncology》 2019年37卷S2期

摘要 : Despite widespread use of decitabine to treat acute myeloid leukaemia (AML), data on its effectiveness and safety in the real-world setting are scanty. Thus, to analyze the performance of decitabine in clinical practice, we pooled... 展开

作者 Galeone~ Carlotta   Pelucchi~ Claudio   Rossi~ Giuseppe   Bocchia~ Monica   Candoni~ Anna   Borlenghi~ Erika   Defina~ Marzia   Fili~ Carla   Cattaneo~ Chiara   Sammartano~ Vincenzo   Fanin~ Renato   Sciume~ Margherita   Sicuranza~ Anna   Imbergamo~ Silvia   Riva~ Marta   Fracchiolla~ Nicola   Latagliata~ Roberto   Caizzi~ Emanuela   Mazziotta~ Francesco   Alunni~ Giulia   Di Bona~ Eros   Crugnola~ Monica   Rossi~ Marianna   Consoli~ Ugo   Fontanelli~ Giulia   Greco~ Giuseppina   Nadali~ Gianpaolo   Rotondo~ Francesco   Todisco~ Elisabetta   Bigazzi~ Catia   Capochiani~ Enrico   Molteni~ Alfredo   Bernardi~ Massimo   Fumagalli~ Monica   Rondoni~ Michela   Scappini~ Barbara   Ermacora~ Anna   Simonetti~ Federico   Gottardi~ Michele   Deliliers~ Daniela Lambertenghi   Michieli~ Mariagrazia   Basilico~ Claudia  
作者单位
期刊名称 《Hematological oncology》
总页数 9
语种/中图分类号 英语 / R73  
关键词 acute myeloid leukaemia   decitabine   first-line therapy   unfit patients  
馆藏号 N2007EPST0000806
相关作者
相关关键词